why choose us

First received: December 20, 2022

Clinical Trial: mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Immunogenicity
Safety
Efficacy

Study Type: Interventional


Official Title: A Randomized, Single-blind, Parallel Controlled Trial to Evaluate the Immunogenicity ,Safety,Efficacy of A Heterologous Booster Dose With SW-BIC-213, in Previously Vaccinated Subjects Against COVID-19

Brief Summary: Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.Secondary#Immunogenicity:To describe binding antibody profile at D01, D29 and D181 of each study group.To describe the neutralizing antibody profile at D15, D29 and D181 of each study intervention group.Secondary#Safety:To assess the reactogenicity and safety of a booster dose in a heterologous…

Read more